CoChat

Age-specific ovarian cancer risks among women with a BRCA1 or BRCA2 mutation

Kotsopoulos, Joanne, Gronwald, Jacek, Karlan, Beth, Rosen, Barry, Huzarski, Tomasz, Moller, Pal, Lynch, Henry T., Singer, Christian F., Senter, Leigha, Neuhausen, Susan L., Tung, Nadine, Eisen, Andrea, Foulkes, William D., Ainsworth, Peter, Sun, Ping, Lubinski, Jan, Narod, Steven A. · 2018 · Gynecologic Oncology
Cited by 109

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

OBJECTIVES For women at high risk of developing ovarian cancer, it is important to provide an accurate recommendation for the optimal age for preventive surgery in order to maximize the preventative effect while delaying symptoms associated with early surgical menopause. The goal of the current study was to estimate age-specific incidence rates of ovarian cancer among women with a BRCA1 or BRCA2 mutation. METHODS From our international registry, we identified 5689 women with no previous diagnosis of ovarian or fallopian tube cancer or preventive oophorectomy. Women were followed from the date of completion of the baseline questionnaire until either a diagnosis of ovarian or fallopian tube cancer, prophylactic oophorectomy, death or last follow-up. The annual and cumulative incidence rates of ovarian cancer were estimated. RESULTS Over a mean follow-up period of 4.7 years (ranges 0-22.6), 195 incident ovarian or fallopian tube cancers were diagnosed (169 [86%] ovarian cancers, 22 [11%] fallopian tube cancers and four [2%] cancers that involved both the ovaries and fallopian tubes). Of these, 45 (23%) cancers were diagnosed at preventive surgery (occult cancers). The cumulative risk of ovarian cancer to age 80 was 49% for BRCA1 and 21% for BRCA2 mutation carriers. The mean age at diagnosis was 51.3 years (ranges 33-84) among women with a BRCA1 mutation and 61.4 years (ranges 44-80) among women with a BRCA2 mutation. CONCLUSION Based on a cumulative risk of 0.55% to age 35 for BRCA1 mutation carriers and of 0.56% to age 45 for BRCA2 mutation carriers, we recommend bilateral salpingo-oophorectomy before age 40, but ideally by age 35, for women with a BRCA1 mutation and by age 45 for those with a BRCA2 mutation to maximize prevention and to minimize adverse effects.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ygyno.2018.05.011

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 109

Metadata

Authors
Kotsopoulos, J., Gronwald, J., Karlan, B., Rosen, B., Huzarski, T., Moller, P., Lynch, H. T., Singer, C. F., Senter, L., Neuhausen, S. L., Tung, N., Eisen, A., Foulkes, W. D., Ainsworth, P., Sun, P., Lubinski, J., & Narod, S. A.
Venue
Gynecologic Oncology
Publisher
Elsevier BV
Published
2018-07
Volume
150
Issue
1
Pages
85-91
ISSN
0090-8258 (ISSN-L)
OpenAlex
W2803852062
Cited by
109
References
3
FWCI
6.52
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Age-specific ovarian cancer risks among women with a BRCA1 or BRCA2 mutation. https://app.cochat.ai/papers/10.1016/j.ygyno.2018.05.011
The paper
Kotsopoulos, J., Gronwald, J., Karlan, B., Rosen, B., Huzarski, T., Moller, P., Lynch, H. T., Singer, C. F., Senter, L., Neuhausen, S. L., Tung, N., Eisen, A., Foulkes, W. D., Ainsworth, P., Sun, P., Lubinski, J., & Narod, S. A. (2018). Age-specific ovarian cancer risks among women with a BRCA1 or BRCA2 mutation. Gynecologic Oncology. https://doi.org/10.1016/j.ygyno.2018.05.011

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.